Blackstone Inc’s PTC Therapeutics PTCT Stock Holding History

Blackstone Inc’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$682K	Sell	8,363 -2,004	-19%	-$145K	﹤0.01%	299
2026 Q1	$706K	Buy	+10,367	New	+$734K	﹤0.01%	268
2025 Q1	–	Sell	-1,059,574	Closed	-$47.8M	–	186
2024 Q4	$47.8M	Sell	1,059,574 -35,716	-3%	-$1.53M	0.22%	45
2024 Q3	$40.6M	Hold	1,095,290	–	–	0.18%	44
2024 Q2	$33.5M	Hold	1,095,290	–	–	0.14%	49
2024 Q1	$31.9M	Hold	1,095,290	–	–	0.13%	54
2023 Q4	$30.2M	Hold	1,095,290	–	–	0.14%	52
2023 Q3	$24.5M	Hold	1,095,290	–	–	0.1%	58
2023 Q2	$44.5M	Hold	1,095,290	–	–	0.19%	47
2023 Q1	$53.1M	Hold	1,095,290	–	–	0.22%	40
2022 Q4	$41.8M	Buy	+1,095,290	New	+$45.5M	0.16%	43

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Blackstone Inc's PTCT Position: Q2 2026 in Review

Blackstone Inc reduced its PTC Therapeutics (PTCT) stake by 19% in Q2 2026, selling an estimated $145K and leaving 8,363 shares worth $682K. The position accounts for ﹤0.01% of the portfolio, ranked #299.

Blackstone Inc first reported a position in PTCT in Q4 2022 and has held it in 11 quarters since. The position peaked at $53.1M in Q1 2023. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Blackstone Inc held 8,363 shares of PTC Therapeutics worth $682K as of Q2 2026.
Blackstone Inc sold 2,004 PTC Therapeutics shares in Q2 2026, an estimated $145K.
PTC Therapeutics made up ﹤0.01% of Blackstone Inc's portfolio in Q2 2026, its #299 holding.
Blackstone Inc first reported a position in PTC Therapeutics in Q4 2022 and has held it in 11 quarters since.
Blackstone Inc's PTC Therapeutics position peaked at $53.1M in Q1 2023.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Blackstone Inc's 13F filing for Q2 2026, filed 14 Aug 2026.